Georgia Bio Responds to Biden Administration’s Federal TRIPS Waiver

“On behalf of Georgia Bio and the biotechnology industry in Georgia, we have grave concerns about the Biden administration’s decision to waive the intellectual property patent for American vaccine technology. Countless hours went into safely researching, developing, and producing these life-saving vaccines, and this decision could ultimately undermine global supply chains and ongoing vaccination efforts worldwide – especially for healthcare systems in low-and middle-income countries. We join our friends at Biotechnology Innovation Organization (BIO) in asking for a more thoughtful, patient-centered approach as we navigate this new challenge in the fight against COVID-19 and subsequent global health crises.” – Maria Thacker-Goethe, President & CEO, Georgia Bio

Read the full Biotechnology Innovation Organization (BIO) statement here.

The post Georgia Bio Responds to Biden Administration’s Federal TRIPS Waiver appeared first on Georgia Bio.

< Older Post

Newer Post >

September GBG Report Now Available – Federal Funding Insights for Georgia Life Sciences Members

September 11, 2025

Members are invited to join G2G’s Monthly GBG Reporting Service Webinar on September 18, 2025 . The first portion ( 12:00–12:30 PM ET ) is free and open to all, offering a high-level overview of current federal funding trends. The second half ( 12:30–1:00 PM ET ) is a premium consultation available only to Georgia Life Sciences members, offering direct access to G2G’s expert team—who have helped secure over $550 million in non-dilutive government funding since 2007. Register here: https://www.g2gconsulting.com/event/non-dilutive-funding-g2gs-monthly-gbg-reporting-service-webinar-14-3/2025-09-18/ Key opportunities this month include DARPA’s Expedited Research Innovation System for CBRN threat defense technologies, BARDA’s I-CREATE diagnostic funding and VANGUARD biomanufacturing tools development (each offering up to $200,000), NIAID tuberculosis and influenza research units (up to $1.5–$2.5 million annually), DoD’s $4 million Advanced Medical Monitor development through MTEC, and multiple SBIR opportunities for sensors and field-deployable diagnostics (up to $209,575 for Phase I awards). The September GBG report highlights 13 immunology and infectious disease opportunities, 10 cognitive and brain health programs, and several biotechnology and biomanufacturing initiatives across federal agencies including the Army, ARPA-H, BARDA, and NSF. Georgia Life Sciences members can access the complete 29-page report with detailed deadlines and eligibility requirements [insert link or portal instructions here]. GLS members can access the full 29-page report with deadlines and submission details by logging into your member portal.